Correlation Between Citigroup and Briacell Therapeutics
Can any of the company-specific risk be diversified away by investing in both Citigroup and Briacell Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citigroup and Briacell Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Citigroup and Briacell Therapeutics Corp, you can compare the effects of market volatilities on Citigroup and Briacell Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citigroup with a short position of Briacell Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citigroup and Briacell Therapeutics.
Diversification Opportunities for Citigroup and Briacell Therapeutics
-0.07 | Correlation Coefficient |
Good diversification
The 3 months correlation between Citigroup and Briacell is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Citigroup and Briacell Therapeutics Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Briacell Therapeutics and Citigroup is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citigroup are associated (or correlated) with Briacell Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Briacell Therapeutics has no effect on the direction of Citigroup i.e., Citigroup and Briacell Therapeutics go up and down completely randomly.
Pair Corralation between Citigroup and Briacell Therapeutics
Taking into account the 90-day investment horizon Citigroup is expected to generate 2.42 times less return on investment than Briacell Therapeutics. But when comparing it to its historical volatility, Citigroup is 6.82 times less risky than Briacell Therapeutics. It trades about 0.12 of its potential returns per unit of risk. Briacell Therapeutics Corp is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest 63.00 in Briacell Therapeutics Corp on September 24, 2024 and sell it today you would lose (8.91) from holding Briacell Therapeutics Corp or give up 14.14% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 98.46% |
Values | Daily Returns |
Citigroup vs. Briacell Therapeutics Corp
Performance |
Timeline |
Citigroup |
Briacell Therapeutics |
Citigroup and Briacell Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Citigroup and Briacell Therapeutics
The main advantage of trading using opposite Citigroup and Briacell Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citigroup position performs unexpectedly, Briacell Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Briacell Therapeutics will offset losses from the drop in Briacell Therapeutics' long position.The idea behind Citigroup and Briacell Therapeutics Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.Briacell Therapeutics vs. Fate Therapeutics | Briacell Therapeutics vs. Sana Biotechnology | Briacell Therapeutics vs. Caribou Biosciences | Briacell Therapeutics vs. Arcus Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Complementary Tools
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |